Top 3 Healthcare Stocks to Buy and Hold in 2026

The post Johnson & Johnson (JNJ) Stock Surges Past Record High as Wall Street Raises Price Targets appeared on BitcoinEthereumNews.com. Key Highlights JNJ reached a record peak of $264.98 before climbing further to $268.69, posting a 3.70% daily gain Year-over-year total returns stand at an impressive 71% Guggenheim elevated its price objective to $270 with a Buy rating, projecting Q2 sales of $25.48 billion The company increased its quarterly payout to $1.34 per share from $1.30, extending its dividend growth streak to 55 years Major institutional players including Vanguard, State Street, and Norges Bank have significantly expanded their stakes Johnson & Johnson shares reached unprecedented territory on Tuesday, initially touching $264.98 before advancing to $268.69 — representing a 3.70% intraday increase. This valuation positions the healthcare giant’s market capitalization at approximately $646.8 billion. Johnson & Johnson, JNJ Over the trailing twelve-month period, shares have cli

Eli Lilly's investment in AI-designed therapeutics could revolutionize treatment options for conditions lacking effective injectable solutions. The post Eli Lilly invests $40M in Absci for AI-designed injectable antibody ABS-201 appeared first on Crypto Briefing.

Mounjaro maker is collaborating with small biotechs on AI as a tool for drug discovery

The investigation risks deepening US-EU trade rifts, potentially disrupting pharmaceutical markets and prompting retaliatory measures from the EU. The post US launches tariff investigation into Germany over pharmaceuticals, escalating trade tensions appeared first on Crypto Briefing.

AI-driven optimization in drug synthesis accelerates R&D timelines, potentially reducing costs and expediting market entry for pharmaceuticals. The post GPT-5.4 improves Chan-Lam coupling yields in drug discovery appeared first on Crypto Briefing.

Companies are betting on big implications for pharmaceuticals, financial services and crypto. But sceptics worry about hype

The post CVS restores Zepbound coverage, adds Eli Lilly’s obesity pill Foundayo appeared on BitcoinEthereumNews.com. An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. Shelby Knowles | Bloomberg | Getty Images CVS Health on Thursday said it will restore coverage of Eli Lilly‘s blockbuster weight loss injection Zepbound and start covering its new obesity pill on its standard drug plans – a win for the drugmaker and certain patients who will be able to access more treatment options. CVS will add Zepbound coverage on Oct. 1, and start covering Lilly’s newly approved Foundayo pill on June 1. The move will boost Lilly’s efforts to maintain its dominance over Novo Nordisk in the blockbuster weight loss drug market, as it puts the two drugmakers on equal footing in major plans.   It comes a year after CVS struck a deal with Novo Nordisk to make its drug Wegovy the preferred obesity treatment on its standard plans, while dro

The post Eli Lilly’s $4 Billion Vaccine Bet appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at the spreading Ebola epidemic, the Midas list health investors, Lilly’s trio of vaccine deals, and more. To get it in your inbox, subscribe here. Health workers leaving the isolation area at Congo’s General Referral Hospital during the Ebola outbreak response. Getty Images In less than two weeks since the Africa Center for Disease Control confirmed an Ebola outbreak in the Democratic Republic of the Congo, more than 220 people have been killed by the disease. The total number of people infected has now topped 1,000, and the disease has spread to neighboring Uganda. On Monday, the head of the World Health Organization, Tedros Adhanom Ghebreyesus, said the disease was spreading faster than response efforts, leaving public health workers “playing catch-up.” The outbreak could surpass the 2018-2020 one, which was the biggest on record and caused more than 2,290